OUHSC Research News – Monday, November 08, 2021
Notices and Reminders
ORA announces a one-month trial of SPINPlus, a comprehensive funding opportunities database by InfoEd Global
ORA has secured a one-month trial of SPINPlus, the world’s largest funding opportunities database. SPINPlus includes the SPIN database of funding opportunities and matching alert service called SMARTS. With SPINPlus, OUHSC researchers, administrators, postdocs, and graduate students can search over 40,000 funding opportunities from more than 12,000 federal, public, non-profit, and private sponsors and create automated alert service, which delivers targeted funding opportunities via email.
Please contact Sogol Rasouli at email@example.com to find out how to register and access SPINPlus, and set up your own funding alerts.
ORA Reminder: Effective October 1st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs).
Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1st, may delay processing your application/award by the ORA staff.
ORA Reminder: As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line. Failure to properly list the OUHSC vs Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award.
Requirements for Acknowledging NIH-Supported Research
NIH funded researchers are required to accurately acknowledge NIH funding in publications, press releases, or other documents about research that is funded by NIH in whole or in part. To comply with NIH requirements, recipients must include the following (as described in Communicating and Acknowledging Federal Funding):
Recipients should only acknowledge NIH awards on publications and other documents when the research activities that contributed to that publication directly arise from the award and are within the scope of the award being acknowledged. Please see the Communicating and Acknowledging Federal Funding and FAQs pages for more information on when, where, and how to acknowledge NIH funding.
NSF has released the updated Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 22-1). This is effective for proposals submitted or due on or after October 4, 2021. Please see the list of PAPPG (NSF 22-1) significant changes and clarifications for all of the updates. Some of the key changes are listed below:
Text Recycling Research Project (TRRP)
The Text Recycling Research Project (TRRP) is a multi-institutional investigation of text recycling (often called “self-plagiarism”) in Science, Technology, Engineering and Mathematics (STEM) disciplines. Text recycling is a common practice in research writing. TRRP aims to provide guidelines to better understand when and how researchers can recycle/reuse material from their own previous work in new documents. For additional guidance and resources, please visit: https://textrecycling.org/
Workshops and Seminars
Save the Date - ORA Noon Conference offered via Zoom
Date: November 30, 2021 at 1:00 pm
Topic: Writing Successful Grants
Description: This talk goes beyond the basics of grant writing to discuss writing the specific aims and considerations for the research strategy, convey the NIH-recommended format and approach for each subsection, address and explain core-review criteria, and discuss scoring conventions, rigor, and reproducibility.
The OU Stephenson Cancer Center 2021 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference
Date: December 2-3, 2021, via Zoom
Description: The OU Stephenson Cancer Center is proud to host the 2021 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference. The END2CANCER conference will start the morning of December 2, 2021 and conclude in the afternoon of December 3, 2021. The conference will bridge laboratory research conducted in the areas of nanotechnology and drug delivery to clinical application for the detection, diagnosis, imaging and treatment of cancer. The conference will host keynote, plenary and invited lectures by eminent scientists who will discuss new and emerging concepts, technologies and challenges in translating nanomedicine from bench-to-bedside.
OUHSC Funding Opportunities
Limited Submission Announcement: Camille Dreyfus Teacher-Scholar Awards Program
Summary: The Camille Dreyfus Teacher-Scholar Awards Program supports the research and teaching careers of talented young faculty in the chemical sciences. Based on institutional nominations, the program provides discretionary funding to faculty at an early stage in their careers. Criteria for selection include an independent body of scholarship attained in the early years of their appointment (see below) and a demonstrated commitment to education, signaling the promise of continuing outstanding contributions to both research and teaching.
The Camille Dreyfus Teacher-Scholar Awards Program provides an unrestricted research grant of $100,000. Funds are normally expended over a period of five years.
Eligibility: Nominees must hold a full-time tenure-track academic appointment and are normally expected to have been appointed no earlier than mid-year 2016. Awardees are from Ph.D. granting departments in which scholarly research is a principal activity. Undergraduate education is an important component. Institutions may submit only one Camille Dreyfus nomination annually. Re-nominations are accepted.
Submission Information: Faculty members who plan to develop a proposal for this solicitation will submit a notice of intent to firstname.lastname@example.org by November 8, 2021. An internal nomination packet must be submitted as a single pdf to email@example.com by November 22, 2021. The internal nomination packet should include the following:
- A letter of nomination from the department chair highlighting the nominee's achievements and the basis for selection (limited to two pages)
- A summary description of the nominee's research accomplishments as an independent faculty member, and a description of research plans (pre-proposal limited to three pages, including references, with use of at least one graphic being encouraged)
- A statement intended to convince the reviewers of the nominee's dedication to education in the chemical sciences (pre-proposal limited to one page)
- A CV (limited to four pages) including a list of publications in which independent contributions and undergraduate coauthors are clearly identified. Research support should be indicated.
Notice of Intent Due: November 8, 2021
Internal Application Due: November 22, 2021
Sponsor Deadline for Full Application: February 2, 2022
Upon notification, the selected PI will be directed to route their application through SoonerTrack so that this can be submitted.
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- BioMarin Pharmaceutical Inc. is looking for early discovery academic research involving targets with genetic evidence in the area of kidney disease – with a focus on ADPKD and Alport Syndrome. Submission entails a 1-pg non-confidential summary of technology (deadline 11/11).
- A global pharmaceutical company (requested anonymity) is interested in early-stage drug discovery and preclinical research to identify next generation small molecule biologics, including antibody approaches and protein therapeutics, to treat kidney diseases with high unmet needs. Novel druggable targets with clear linkage to human disease are also of interest. Out of scope: renal cancer, dialysis complication, renal transplantation, cell and exosome therapies. Submission entails a 1-pg non-confidential summary of technology (deadline 11/17).
- Ultragenyx is interested in collaborating with academia in research focused on innovative gene regulation technologies for AAV-based gene therapy for rare and ultra-rare diseases. Out of scope: non-AAV viral vector approaches (e.g., lentivirus vector), non-viral vector approaches. Submission entails a 1-pg non-confidential summary of technology (deadline 11/17).
- A global medical device company (requested anonymity) is interested in innovations for minimally invasive interventional treatment for chronic kidney disease and underlying conditions. Out of scope: dialysis modalities. Submission entails a 1-pg non-confidential summary of technology (deadline 12/1).
New Clinical Study Opportunities (Please note this is NOT a solicitation for study subjects)
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
- Clinical Trial Opportunity in Sickle Cell Disease study - IQVIA Biotech LLC
- Valo Health Phase 2 Cardiovascular Trial For Post-Myocardial Infarction Patients
- Phase 2 Acute Myeloid Leukemia (AML) Clinical Trial
Please contact Scott Davis at firstname.lastname@example.org if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
Other Funding Opportunities
Mary Kay Ash Foundation 2022 Cancer Research Grants
Description: The Mary Kay Ash FoundationSM is a non-profit public foundation, which focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others). Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. The Foundation is pleased to invite your institution to submit one grant proposal. Please note only one grant application will be accepted from each accredited, invited institution.
The grant will be up to $100,000 (combined direct and indirect costs) for a two-year period. The Foundation anticipates funding between 10 and 15 grants. Please review the attached RFP with FAQs section as well as the Applicant User Guide for additional information.
Proposals Due: February 4, 2022 at 11:59 PM (CT)
Please complete your application here: https://apply.yourcausegrants.com/apply/programs/7d085160-a542-4415-bea4-1fbe139b51ee*
Please reach out to Julia Santosuosso if you have any questions at Julia.Santosuosso@mkcorp.com.
The American Heart Association (AHA) - Request for Applications (RFA) for a Strategically-Focused Research Network (SFRN) on the Science of Diversity in Clinical Trials (SDCT).
Description: With the establishment of the SFRN on the Science of Diversity in Clinical Trials, the AHA will identify solutions underlying the inequitable participation of diverse individuals in clinical research, and the associated health inequities it creates.
The network will consist of at least three Network Centers, each of which will propose novel research strategies to engage individuals from under-represented groups in clinical trials such that their participation in clinical trials aligns with the diversity of our communities. Each Network Center application will include two or three research projects with a common fundamental theme that will assess an intervention or approach to addressing diversity in clinical trials and must have the necessary research team, required infrastructure and ability to recruit and retain a diverse group of study participants. Each center may request up to $4.3 million over four years.
In addition, a Training Center will be established as part of the Network to incorporate a multidisciplinary approach to provide robust research experiences, training, and mentorship for Center Fellows. All SDCT Fellows will be from groups who are under-represented in science and medicine. The maximum budget amount a Training Center applicant may request is $500,000 over four years.
Pre-proposals Due: December 7, 2021
Link to Full Announcement: https://professional.heart.org/en/research-programs/strategically-focused-research/strategically-focused-research-networks/2022-science-of-diversity-in-clinical-trials-research-network
Cystic Fibrosis Foundation
The following RFAs have a full application deadline of December 9, 2021:
Additional Open Funding Opportunities can be found at https://cff.org/Research/Researcher-Resources/Awards-and-Grants/Funding-Opportunities/
Asahi Kasei Pharma Call for Collaboration proposal
Description: Asahi Kasei Pharma is publicly calling for new proposals related to drug discovery research as part of its efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. Proposals are solicited concerning new drug seeds (drug target and drug candidate) and technologies in the therapeutic fields of autoimmune disease, critical care medicine, neurodegenerative disease, pain and neuropathy, bone disease, and drug discovery platform technology.
Submissions will be assessed for their potential for collaborative research.
Proposals Due: February 28, 2022
Link to Full Announcement: www.asahikasei-pharma.co.jp/a-compass/en/
Midwest Biomedical Accelerator Consortium (MBArC)
Description: MBArC deploys up to $1million/year in training, proof-of-concept milestone/deliverable-driven funding and support to accelerate the translation of your technology into a commercial product. The Program is designed to bridge the gap between academic research and industry by providing resources to researchers from 16 institutions in the Midwest to perform experiments and generate data that can attract follow-on funding from federal sources, investors and strategic partners to continue commercialization of the technology. All technologies (i.e., Therapeutic, Diagnostic, Device, Tool and Software) with the potential to directly impact human health are considered for funding. Technologies that are already licensed or optioned to a company are not eligible. Select applicants are required to attend a Commercialization Boot Camp that is offered annually by the Program. MBArC supports each project with a maximum of $100,000, and the applicant is required to show at least an equal (1:1) cash match commitment from non-federal sources (e.g., recipient institutions, foundations, for-profit investors, other state resources) to be eligible for funding.
Proposals Due: The 2022 Call for Letters of Intent is scheduled to go out in late October, 2021.
Link to Full Announcement: https://medicine.missouri.edu/offices-programs/midwest-biomedical-accelerator-consortium/mbarc-application-requirements
If you would like to learn more about the Program and/or would like to be notified about our 2022 Call for Letters of Intent, please contact the MBArC Program Office:
Jaya Ghosh, PhD (Lead Program Manager) | email@example.com
Kristin Hatton (Assistant Program Manager) | firstname.lastname@example.org
Chan Zuckerberg Initiative (CZI) Single-Cell Biology Data Insights RFA
Description: Given the growth of the single-cell biology field and the rapid increase in available data, the Chan Zuckerberg Initiative (CZI)’s newest funding opportunity seeks to support computational experts to advance tools and resources that make it possible to gain greater insights into health and disease from existing single-cell biology datasets. The CZI Single-Cell Biology Data Insights Request for Applications (RFA) invites applications for projects that will advance the fields of single-cell biology and data science. Projects should address computational challenges and bottlenecks associated with boosting the utility and insight from available single-cell biology datasets. Projects may include dedicated efforts to improve existing computational tools and standards, benchmarking classes of tools, integration of available datasets to enable greater biological insight, development of new features that support interoperability of current data or tools, and other major challenges brought forward.
Proposals Due: December 14, 2021
Link to Full Announcement: https://chanzuckerberg.com/rfa/single-cell-data-insights/
The Mselanoma Research Alliance (MRA) 2021-2022 Request for Proposal
Young Investigator and Pilot Awards Full Proposals Due: November 17, 2021
Team Science Award Full Proposals Due (from invited applicants) Due: January 19, 2022
Description: MRA anticipates supporting at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Special Opportunities are also available in immunotherapy, women in research, and patient-centric clinical trials. MRA encourages applications from a diverse pool of investigators. Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found on the MRA website at CureMelanoma.org/RFP
Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/
OKLAHOMA NSF EPSCoR Summer 2022 Research Experience for Undergraduate Students (REU)
Description: OKLAHOMA NSF EPSCoR REU awards provide opportunities for undergraduate students from regional universities and colleges across the state to perform research in collaboration with Oklahoma’s comprehensive research campuses (OU, OSU, TU, NRI) during the summer months. The goal of the program is to enhance pursuit of graduate degrees by students at regional undergraduate institutions and strengthen network collaborations across all higher education institutions in Oklahoma. Students benefit from hands-on research experiences in STEM fields and one-on-one guidance from faculty mentors. Proposals will be awarded via a competitive review process based on proposal integrity and the engagement of a diversity of students from regional institutions.
Proposals Due: November 17, 2021
Link to Full Announcement: http://www.okepscor.org/2022-research-experience-undergraduates
Oklahoma Center for Adult Stem Cell Research (OCASCR)
Grant Deadline: January 28, 2022